Id: acc1864
Group: 2sens
Protein: ULK1
Gene Symbol: ULK1
Protein Id: O75385
Protein Name: ULK1_HUMAN
PTM: methylation
Site: Arg170
Site Sequence: VKIADFGFARYLQSNMMAATL
Disease Category: Cancer
Disease: Lung Cancer
Disease Subtype: NSCLC
Disease Cellline: A549
Disease Info:
Drug: carboplatin
Drug Info: "Carboplatin is a platinum-based chemotherapeutic agent that inhibits DNA synthesis by forming DNA cross-links, thereby suppressing replication and transcription and inducing apoptosis in cancer cells; it is widely used for the treatment of various malignancies, including ovarian, lung, and testicular cancers. "
Effect: resist
Effect Info: Overexpression of PRMT5 promotes the methylation of ULK1 and enhances the resistance of cancer cells to carboplatin.
Note:
Score: 5.0
Pubmed(PMID): 37381616
Sentence Index:
Sentence:

Sequence & Structure:

MEPGRGGTETVGKFEFSRKDLIGHGAFAVVFKGRHREKHDLEVAVKCINKKNLAKSQTLLGKEIKILKELKHENIVALYDFQEMANSVYLVMEYCNGGDLADYLHAMRTLSEDTIRLFLQQIAGAMRLLHSKGIIHRDLKPQNILLSNPAGRRANPNSIRVKIADFGFARYLQSNMMAATLCGSPMYMAPEVIMSQHYDGKADLWSIGTIVYQCLTGKAPFQASSPQDLRLFYEKNKTLVPTIPRETSAPLRQLLLALLQRNHKDRMDFDEFFHHPFLDASPSVRKSPPVPVPSYPSSGSGSSSSSSSTSHLASPPSLGEMQQLQKTLASPADTAGFLHSSRDSGGSKDSSCDTDDFVMVPAQFPGDLVAEAPSAKPPPDSLMCSGSSLVASAGLESHGRTPSPSPPCSSSPSPSGRAGPFSSSRCGASVPIPVPTQVQNYQRIERNLQSPTQFQTPRSSAIRRSGSTSPLGFARASPSPPAHAEHGGVLARKMSLGGGRPYTPSPQVGTIPERPGWSGTPSPQGAEMRGGRSPRPGSSAPEHSPRTSGLGCRLHSAPNLSDLHVVRPKLPKPPTDPLGAVFSPPQASPPQPSHGLQSCRNLRGSPKLPDFLQRNPLPPILGSPTKAVPSFDFPKTPSSQNLLALLARQGVVMTPPRNRTLPDLSEVGPFHGQPLGPGLRPGEDPKGPFGRSFSTSRLTDLLLKAAFGTQAPDPGSTESLQEKPMEIAPSAGFGGSLHPGARAGGTSSPSPVVFTVGSPPSGSTPPQGPRTRMFSAGPTGSASSSARHLVPGPCSEAPAPELPAPGHGCSFADPITANLEGAVTFEAPDLPEETLMEQEHTEILRGLRFTLLFVQHVLEIAALKGSASEAAGGPEYQLQESVVADQISLLSREWGFAEQLVLYLKVAELLSSGLQSAIDQIRAGKLCLSSTVKQVVRRLNELYKASVVSCQGLSLRLQRFFLDKQRLLDRIHSITAERLIFSHAVQMVQSAALDEMFQHREGCVPRYHKALLLLEGLQHMLSDQADIENVTKCKLCIERRLSALLTGICA

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

No data.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC

No data.

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
S 556 D Psoriasis Phosphorylation 34421918
S 317 D Melanoma Phosphorylation 34759263
S 757 D Melanoma Phosphorylation 34759263
S 556 D Gastric cancer Phosphorylation 33037394
S 555 D Melanoma Phosphorylation 34759263
K 571 P Breast cancer Ubiquitination 35670107
S 757 P Non-small cell lung cancer/carcinoma Phosphorylation 23921130
K 568 P Breast cancer Ubiquitination 35670107
S 495 P Breast cancer Phosphorylation 35670107
S 495 U Glioma Phosphorylation 31378785
S 757 U Melanoma Phosphorylation 34759263
S 555 U Melanoma Phosphorylation 34759263
S 533 U Glioma Phosphorylation 31378785
K 68 U Acute liver failure Acetylation 33431796
S 469 U Glioma Phosphorylation 31378785
S 317 U Melanoma Phosphorylation 34759263
S 317 U Late onset Parkinson's disease Phosphorylation 35605642
S 555 U Granulomatosis with polyangiitis Phosphorylation 37720230

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: